JPMorgan Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)

Biohaven (BHVN) stock plunges 20% on drug updates, RBC says buy the weakness

May 29, 2024 10:16 AM EDT

Biohaven (NYSE: BHVN) saw its stock plunge more than 20% following the market open on Wednesday, after the company released interim data from a Phase 1 study of its autoimmune drug candidate BHV-1300.

The data showed dose-dependent and rapid reductions in IgG levels within hours of administration. There were no severe adverse events reported, with... More

RBC Capital Defending Biohaven Pharmaceutical Holding (BHVN): 'We Would Be Buyers on Weakness'

May 29, 2024 9:14 AM EDT

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $59.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst comments "This morning BHVN published a press release ahead of their R&D day summarizing the key takeaways, and while we expect additional granularity at the R&D day itself, we note the additional IgG degrader data is supportive of further development in our view. There was clear dose dependence in the data, with 5%, 15%, 30% and 37% pbo-adjusted maximal mean IgG reduction across the first 4 cohorts, which is consistent with the company's modeling.... More

Biohaven Pharma (BHVN) Falls 31% Following Updates from Annual Investor R&D Day

May 29, 2024 8:08 AM EDT

Biohaven Pharma (NYSE: BHVN) Falls 31% Following Updates from Annual Investor R&D Day

Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE) platformBHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administrationNo SAEs, no severe AEs, most AEs were mild, deemed unrelated to study drug and resolved spontaneouslyNo clinically significant changes in LFTs... More

Biohaven Pharma (BHVN) Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Invest

May 29, 2024 7:31 AM EDT

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of... More

TD Cowen Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)

May 28, 2024 9:50 AM EDT

TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $55.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst commented, "Ahead of the important BHV-1300 SAD data update at the R&D day tomorrow, we provide a brief preview and... More